Drug Interactions between Detectnet and octreotide
This report displays the potential drug interactions for the following 2 drugs:
- Detectnet (copper Cu 64 dotatate)
- octreotide
Interactions between your drugs
octreotide copper cu 64 dotatate
Applies to: octreotide and Detectnet (copper Cu 64 dotatate)
ADJUST DOSING INTERVAL: Coadministration of copper Cu 64 dotatate with non-radioactive somatostatin analogs may diminish the diagnostic effects of copper Cu 64 dotatate positron emission tomography (PET) imaging. Somatostatin analogs competitively bind to the same somatostatin receptor as copper Cu 64 dotatate, which may prevent the uptake of copper Cu 64 dotatate into tissues and affect the diagnostic imaging results.
MANAGEMENT: PET imaging with copper Cu 64 dotatate should be performed prior to dosing with somatostatin analogs. For patients receiving short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging. For patients receiving long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging.
References
- (2020) "Product Information. Detectnet (copper cu 64 dotatate)." Currax Pharmaceuticals LLC
Drug and food interactions
octreotide food
Applies to: octreotide
MONITOR: Due to their gastrointestinal pharmacologic effects, somatostatin analogs (e.g., octreotide, lanreotide) may variously affect the absorption of dietary nutrients and concomitantly administered oral medications. Somatostatin analogs have been shown to prolong gastrointestinal transit time and inhibit intestinal absorption of some nutrients such as fat. Clinical data are limited, however. In case reports, octreotide has been reported to reduce the relative bioavailability of cyclosporine. Transplant rejection and significant reductions in cyclosporine levels, sometimes to undetectable levels, have been reported in association with the interaction. Vitamin K absorption was not affected when concomitantly administered with lanreotide according to the manufacturer.
MANAGEMENT: Clinicians should be aware of the potential for altered absorption of concomitantly administered oral medications during treatment with somatostatin analogs. Blood levels and clinical response should be monitored, particularly for drugs that have a narrow therapeutic index, and the dosages adjusted as necessary.
References
- Landgraf R, Landgraf-Leurs MM, Nusser J, et al. (1987) "Effect of somatostatin analogue (SMS201-995) on cyclosporine levels." Transplantation, 44, p. 724-5
- Ho PJ, Boyajy LD, Greenstein E, Barkan AL (1993) "Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly." Dig Dis Sci, 38, p. 309-15
- Katz MD, Erstad BL (1989) "Octreotide, a new somatostatin analogue." Clin Pharm, 8, p. 255-73
- (2001) "Product Information. Sandostatin (octreotide)." Sandoz Pharmaceuticals Corporation
- (2007) "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.